Antimicrobial Peptides

Antimicrobial peptides (AMPs) are small cationic peptides that disrupt microbial membranes, modulate host innate immunity, or both — produced by virtually every multicellular organism as a foundational defense against bacterial, fungal, and viral pathogens. The modern AMP field began with Michael Zasloff's 1987 isolation of the magainins from the skin of African clawed frogs Xenopus laevis (Zasloff M, PNAS 1987, PMID 3299384), establishing that amphibian skin secretes broad-spectrum antimicrobial peptides as part of innate immune defense. Subsequent work expanded the field to dozens of peptide classes across kingdoms — defensins, cathelicidins, histatins, dermcidins, lactoferricins, anionic peptides, cyclic peptides, and many others — with the 2002 Nature review by Zasloff (PMID 11807545) consolidating the field at the time and establishing the conceptual framework that has guided AMP drug development since.

In humans, the principal AMPs include LL-37 (the C-terminal active fragment of human cathelicidin hCAP-18, expressed in keratinocytes, neutrophils, mucosal epithelia, and other tissues — the only human cathelicidin), the alpha-, beta-, and theta-defensins (cysteine-rich peptides predominantly from neutrophils, Paneth cells, and epithelial tissues), the histatins (salivary antimicrobial peptides), dermcidin (sweat-gland-secreted antimicrobial), and various tissue-specific peptides. The family also includes peptides at the periphery of strict 'antimicrobial' definition: KPV (the C-terminal tripeptide of alpha-MSH with anti-inflammatory activity in colitis models, sometimes grouped with AMPs because of its host-defense framing), lactoferricin (the antimicrobial fragment of lactoferrin), DS-5 (a research-tier antimicrobial peptide), tuftsin (the immunomodulator-rather-than-strict-antimicrobial), hepcidin (the iron-regulatory peptide that has antimicrobial side activities through iron sequestration), and larazotide (the gut-barrier modulator with adjacent host-defense framing).

The drug-development landscape for AMPs has produced limited clinical translation despite the substantial preclinical literature. Polymyxins (polymyxin B, colistin) — cyclic lipopeptide AMPs from Bacillus polymyxa — have been clinically used since the 1950s for resistant Gram-negative infections. Pexiganan (a magainin-2 analog) was studied for diabetic foot ulcers but did not reach FDA approval. Daptomycin and dalbavancin sit adjacent to the strict AMP class as lipopeptide antibiotics with related mechanisms. The principal contemporary clinical interest in AMPs is for antimicrobial-resistant infections, mucosal immunity, and inflammatory disease applications including the LL-37 and KPV-related research lines.

This page is the family-level pillar covering the AMP class as a whole. For individual peptide pages with full evidence ratings, dosing, references, and mechanistic detail, follow the links to each member below.

Shared mechanism

Most antimicrobial peptides act through one of two principal mechanisms or a combination: (1) direct microbial membrane disruption — the cationic peptides bind to negatively charged microbial membranes (which differ from the neutral or positively charged outer leaflets of mammalian cells, providing some selectivity), insert into the membrane in various oligomeric configurations (barrel-stave pores, toroidal pores, carpet model), and disrupt membrane integrity to kill the microbe; or (2) intracellular targeting — some AMPs cross membranes and bind intracellular targets such as nucleic acids, ribosomes, or specific proteins, killing the microbe through mechanism distinct from membrane disruption. Many AMPs use both mechanisms in combination.

A distinct and increasingly important AMP function is immunomodulation. AMPs including LL-37 and the defensins act as chemoattractants for immune cells, modulate dendritic cell maturation, regulate cytokine production, influence epithelial barrier function, and shape the integrated host response to infection beyond the direct antimicrobial component. The 'host defense peptide' framing emphasizes this immunomodulatory role alongside the strict antimicrobial mechanism — many modern AMP drug development programs target the immunomodulatory effects rather than direct microbial killing.

Receptor pharmacology is more diverse than the mu/delta/kappa unification of opioid pharmacology. LL-37 and other AMPs interact with formyl peptide receptors (FPR2/ALX), epidermal growth factor receptor, P2X7, and various other targets through multiple mechanism — making the receptor-pharmacology story for AMPs more complex than for many other peptide families. The cathelicidin and defensin mechanism classes are well-characterized; the broader AMP class includes peptides with very diverse modes of action.

History & discovery

The antimicrobial peptide field has multiple discovery threads converging through the 1970s, 1980s, and 1990s. Boman and colleagues' work on cecropins from the silkworm moth (1980) established the insect-AMP framework. Lehrer and Selsted's work on neutrophil defensins (early 1980s) established the mammalian alpha-defensin class. The transformative moment for the broader field was Michael Zasloff's 1987 isolation of the magainins from Xenopus laevis skin (Zasloff M, PNAS 1987, PMID 3299384) — establishing that vertebrate epithelial tissues secrete broad-spectrum antimicrobial peptides as foundational innate immune defense. The magainin discovery generated substantial drug-development interest through the 1990s and 2000s, and Zasloff's 2002 Nature review (PMID 11807545) consolidated the field at a major-review level.

LL-37 emerged as the principal human cathelicidin through work in the 1990s. Cathelicidins are an evolutionarily conserved family of antimicrobial peptides characterized by a conserved N-terminal cathelin domain that is cleaved to release the C-terminal active peptide. Humans have only one cathelicidin (the hCAP-18 / CAMP gene product), with LL-37 as the proteolytically released 37-residue active fragment. LL-37 is expressed in neutrophils (where it accumulates in specific granules), keratinocytes, mucosal epithelia, sweat and salivary glands, and other tissues — providing barrier antimicrobial defense at multiple anatomical sites. LL-37 has direct antimicrobial activity against bacteria, fungi, and enveloped viruses, plus immunomodulatory activities including chemotaxis, dendritic cell modulation, and effects on epithelial barrier function.

Defensins emerged from Lehrer's group at UCLA in the 1980s and 1990s — alpha-defensins from neutrophils (HNP-1 to HNP-4) and Paneth cells (HD-5, HD-6), beta-defensins from epithelia, and theta-defensins (cyclic peptides found in nonhuman primates). The defensin literature has been extensive in basic immunology but has produced limited direct clinical translation; defensins are part of the host-defense biology rather than therapeutic agents.

Lactoferricin was characterized in the 1990s as the antimicrobial peptide fragment released from lactoferrin (the iron-binding glycoprotein abundant in milk and neutrophil granules) by pepsin cleavage. The bovine and human lactoferricin variants have been studied for oral antimicrobial applications, biofilm disruption, and (more recently) anti-cancer cell-membrane-targeting effects. Lactoferricin sits at the periphery of strict 'AMP' definition because its parent protein (lactoferrin) has multiple antimicrobial mechanisms beyond the lactoferricin fragment — but the fragment itself is a true cationic AMP.

KPV's positioning within the AMP family is somewhat unusual. KPV is the C-terminal tripeptide of alpha-MSH (Lys-Pro-Val), with anti-inflammatory activity in inflammatory bowel disease models and modest direct antimicrobial activity. It is sometimes grouped with AMPs because of the host-defense framing and the alpha-MSH parent peptide's role in melanocortin signaling that overlaps with immune modulation, but it is more accurately characterized as an immunomodulatory peptide rather than a classical AMP. Its place in the AMP family is more by association than by strict mechanism.

The drug-development translation has been limited despite the substantial preclinical literature. Polymyxin B and colistin (polymyxins from Bacillus polymyxa, cyclic lipopeptide antibiotics from the AMP family in a structural sense) have been clinically used since the 1950s and have re-emerged as last-resort options for multidrug-resistant Gram-negative infections including Pseudomonas, Acinetobacter, and Enterobacteriaceae. Pexiganan (Locilex), a magainin-2 analog, completed Phase 3 trials for diabetic foot ulcer infection but did not reach FDA approval despite some efficacy signals. Iseganan (an antimicrobial peptide for oral mucositis), omiganan (a cathelicidin analog), and various other AMP drug candidates have advanced through clinical development without producing FDA-approved entries. The translation gap reflects the technical challenges of AMP drug development — peptidase degradation, host-toxicity windows, formulation complexity, and the difficulty of demonstrating clinical superiority over existing antibiotic classes for the most common indications.

Contemporary AMP drug development continues to focus on antibiotic-resistant infection settings (where AMPs may have unique advantages over conventional antibiotics that resistance has eroded), mucosal and topical applications (where the peptidase-degradation issue is reduced), inflammatory disease (where AMPs' immunomodulatory effects matter alongside or instead of direct antimicrobial activity), and biotechnology applications (food preservation, biofilm management, agricultural use). LL-37 and the broader cathelicidin literature continue to generate research interest. KPV continues to be discussed in inflammatory bowel disease and gut-immune contexts.

State of evidence

Evidence in this class is asymmetric. The basic immunology and antimicrobial mechanism literature is extensive — five decades of research since the cecropin and magainin discoveries have produced one of the most thoroughly characterized innate-immunity systems in modern biology. The clinical translation has been limited, with polymyxins (clinically used since the 1950s) and various AMP-derived antibiotics (daptomycin, dalbavancin) representing the principal FDA-approved clinical translations. Direct AMP drug development has produced multiple Phase 3 candidates without reaching approval (pexiganan, iseganan, omiganan).

For patients, the practical takeaway is that antimicrobial peptides are foundational innate-immunity biology with substantial drug-development interest but limited current clinical translation. Polymyxin B and colistin remain in use as last-resort options for resistant Gram-negative infections — important clinical agents but with known toxicity (nephrotoxicity, neurotoxicity) that limits routine use. Topical and mucosal AMP applications continue in development for indications including chronic wound infection, diabetic foot ulcer, oral mucositis, and respiratory infection. Anti-inflammatory peptide use (KPV, lactoferricin) for inflammatory bowel disease and gut-barrier indications has limited clinical evidence. The AMP class is positioned for potential larger clinical translation if the technical challenges of peptide drug development can be addressed alongside the increasingly urgent need for new antimicrobial classes against multidrug-resistant pathogens.

How members compare

Within the family, the principal axes are mechanism (direct membrane disruption vs immunomodulation vs intracellular targeting) and origin (host vs microbial vs synthetic). Among human AMPs, LL-37 is the principal cathelicidin; the alpha- and beta-defensins are the principal defensin classes. Among external/non-human AMPs, the magainins, cecropins, polymyxins, and others have distinct mechanism profiles. Among hybrid or related peptides, KPV, lactoferricin, hepcidin, larazotide, and tuftsin sit at the periphery with mechanism profiles that overlap antimicrobial and immunomodulatory pharmacology.

Outside the antimicrobial peptide family, the closest comparators are the conventional antibiotic drug classes (beta-lactams, fluoroquinolones, macrolides, aminoglycosides, glycopeptides, oxazolidinones, tetracyclines, and many others) — most of which act through specific intracellular targets (bacterial cell wall synthesis, protein synthesis, DNA gyrase, ribosomes, etc.) rather than the membrane-disruption mechanism that characterizes most AMPs. The membrane-disruption mechanism is hypothesized to produce a different resistance profile than target-specific antibiotics — bacteria can mutate to alter a specific drug target relatively easily, but membrane lipid composition is more constrained and harder to mutate without compromising viability. This is one of the principal hopes for AMP drug development against antibiotic-resistant infections. For non-infection indications (inflammatory bowel disease, gut barrier function), the AMP-class peptides KPV and lactoferricin sit alongside conventional therapeutics (mesalamine, biologics, etc.) as adjunct or alternative options without typically displacing the standards of care.

Frequently asked questions

References

• Magainins, a class of antimicrobial peptides from Xenopus skin: isolation, characterization of two active forms, and partial cDNA sequence of a precursorOriginal Research

  Zasloff M, Proceedings of the National Academy of Sciences 1987. The discovery paper isolating magainins from the skin of African clawed frogs Xenopus laevis — establishing that vertebrate epithelial tissues secrete broad-spectrum antimicrobial peptides as foundational innate immune defense. Foundational paper of the modern AMP field.

• Antimicrobial peptides of multicellular organismsReview

  Zasloff M, Nature 2002. The standard major-review consolidation of the AMP field at the time, establishing the conceptual framework that has guided AMP drug development since. Covers the diversity of antimicrobial peptide classes across kingdoms, the membrane-disruption and immunomodulatory mechanisms, and the drug-development implications.

Related goals